Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N. Amaria(The University of Texas MD Anderson Cancer Center), Sangeetha M. Reddy(The University of Texas MD Anderson Cancer Center), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Merrick I. Ross(The University of Texas MD Anderson Cancer Center), Isabella C. Glitza(The University of Texas MD Anderson Cancer Center), Janice N. Cormier(The University of Texas MD Anderson Cancer Center), Carol M. Lewis(The University of Texas MD Anderson Cancer Center), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Ehab Hanna(The University of Texas MD Anderson Cancer Center), Adi Diab(The University of Texas MD Anderson Cancer Center), Michael K. Wong(The University of Texas MD Anderson Cancer Center), Richard E. Royal(The University of Texas MD Anderson Cancer Center), Neil D. Gross(The University of Texas MD Anderson Cancer Center), Randal S. Weber(The University of Texas MD Anderson Cancer Center), Stephen Y. Lai(The University of Texas MD Anderson Cancer Center), Richard A. Ehlers(The University of Texas MD Anderson Cancer Center), Jorge Blando(The University of Texas MD Anderson Cancer Center), Denái R. Milton(The University of Texas MD Anderson Cancer Center), Scott E. Woodman(The University of Texas MD Anderson Cancer Center), Robin Kageyama(Parker Institute for Cancer Immunotherapy), Daniel K. Wells(Parker Institute for Cancer Immunotherapy), Patrick Hwu(The University of Texas MD Anderson Cancer Center), Sapna P. Patel(The University of Texas MD Anderson Cancer Center), Anthony Lucci(The University of Texas MD Anderson Cancer Center), Amy C. Hessel(The University of Texas MD Anderson Cancer Center), Jeffrey E. Lee(The University of Texas MD Anderson Cancer Center), Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), Lauren Simpson(The University of Texas MD Anderson Cancer Center), Elizabeth M. Burton(The University of Texas MD Anderson Cancer Center), Liberty Posada(The University of Texas MD Anderson Cancer Center), Lauren E. Haydu(The University of Texas MD Anderson Cancer Center), Linghua Wang(The University of Texas MD Anderson Cancer Center), Shaojun Zhang(The University of Texas MD Anderson Cancer Center), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Courtney W. Hudgens(The University of Texas MD Anderson Cancer Center), Vancheswaran Gopalakrishnan(The University of Texas MD Anderson Cancer Center), Alexandre Reuben(The University of Texas MD Anderson Cancer Center), Miles C. Andrews(The University of Texas MD Anderson Cancer Center), Christine N. Spencer(The University of Texas MD Anderson Cancer Center), Víctor G. Prieto(The University of Texas MD Anderson Cancer Center), Padmanee Sharma(The University of Texas MD Anderson Cancer Center), James P. Allison(The University of Texas MD Anderson Cancer Center), Michael T. Tetzlaff(The University of Texas MD Anderson Cancer Center), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center)
Cited by 821Open Access
Abstract
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al.|New England Journal of Medicine|2012|12.6k